Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. - Wikidata - wikimedia - TriplyDB

Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

http://www.wikidata.org/entity/Q37168393

about

Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma.Novel targeted therapies for eosinophil-associated diseases and allergy A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions.Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display system Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.Immunological aspects of rabies: a literature review.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.Bifunctional Drugs for the Treatment of Respiratory Diseases.A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.Immuno-evasive tactics by schistosomes identify an effective allergy preventative.The making of bispecific antibodies Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.Improved assembly of bispecific antibodies from knob and hole half-antibodies.Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy.Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity.Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals.Bispecific antibodies in cancer immunotherapy.Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

P2860

Q31091923-35B37322-A796-4B39-A488-8953C17AA1F9 Q34388348-E3D7D09C-7DCE-4ECA-9647-12995C0450E8 Q34444620-58FB20CB-593F-4239-9256-7460E2F73622 Q35117636-982BE305-03C0-4F29-AAE5-E4D4A1940DEF Q35859635-8B42FDB0-E160-4B2F-AC1E-7006984F377D Q36818290-0612C426-DD8B-4A57-B289-D40097DA43A1 Q37631316-D54E3DDA-BB58-481C-90D2-7F5EF78ACAC2 Q38654706-65BEB05D-C6CB-43F8-BF16-CD6693C43B6C Q38861238-1CFD9D65-DADD-4CAF-B610-252307587DF8 Q38992596-F55C42EF-4375-43F8-B644-C81C458A951F Q40066330-9D6F3263-4537-4718-9670-9E997194A5DA Q41373939-9665D8A9-7913-4A8D-9214-F001177A0000 Q42323236-2521E792-7DB3-49A3-8093-96184521FC84 Q42392973-274102BC-DC09-4DEC-ABE6-D2CE209F31F1 Q46711768-028A66E0-A5E1-4D9B-9447-66641508BAA8 Q48256010-25562AD4-E268-403A-84B0-B756558700B7 Q49718154-64CCDFA5-7AC2-40FE-B504-F314C52699AE Q50140611-7E35F31F-E951-4B5B-9E07-B79AB7D4F740 Q51309023-919E09F7-5BF8-4A13-ACBF-05DCB26B4EC8 Q58724935-3780F3C7-CF07-41A7-B7E5-5AA1BAEE2106

P2860

Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

http://www.wikidata.org/entity/Q37168393

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Development of a human IgG4 bi ...... erleukin-13 (IL-13) cytokines.

@en

Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4

@nl

type

label

Development of a human IgG4 bi ...... erleukin-13 (IL-13) cytokines.

@en

Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4

@nl

prefLabel

Development of a human IgG4 bi ...... erleukin-13 (IL-13) cytokines.

@en

Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4

@nl

P1433

Q37168393-AB5DD588-47FC-4078-AA42-AC84E52EDD94

P1476

Q37168393-3EEF1854-CCB1-4AE6-A661-249E42BCD2EF

P2093

Q37168393-21C22A29-CAD0-41C0-B1ED-5C182B5638C0

Q37168393-27B01231-D73C-4554-9AEB-1B6CCBC87F03

Q37168393-28837A16-D0F3-4B39-B0F4-1D1EA9FF903C

Q37168393-2B053833-33D4-485C-9A0E-1ED57D7D81F4

Q37168393-3B8B49AE-C5B2-4D20-9966-BC3C0F85C150

Q37168393-49C6CD01-54EE-4346-9932-1633855A20A9

Q37168393-552FFC8A-C854-4274-87B8-002A5DB38289

Q37168393-5AA5C063-CDE5-4E62-98B0-B3F8843743EA

Q37168393-66A54AF8-7B0A-419B-AA46-0CA62856368D

Q37168393-6970A947-A415-4B38-91B1-BE08DBD4A5E1

P2860

Q37168393-034B9C34-6785-4023-9235-C9D6507EC8FE

Q37168393-08C91520-8CBD-4049-9864-F16D7DEE4788

Q37168393-09F05484-697C-4CF1-BBC1-E8E63C8B5145

Q37168393-11687B5C-1544-4EE3-A5FA-B236C1605103

Q37168393-12FC7755-4F9C-47B6-B2C3-F770B1A11901

Q37168393-15E7686E-B7FA-4678-8714-AB1CA68FAD75

Q37168393-16FFA85C-A2DB-41B8-A19D-0768E106D19C

Q37168393-2038F09B-84AE-4080-BA65-12C496692B01

Q37168393-22F4FF16-18F6-4425-A71E-84000A1B6C9E

Q37168393-2C12D938-F0B8-43C0-9CBE-13656D236270

P304

Q37168393-C70AC83D-CD14-4DA9-9987-AD902E1F2DE6

P31

Q37168393-838ED717-0C02-492F-8E31-C409AEB32555

P356

Q37168393-1A84B3C4-0327-4C51-8847-EDA81DC2A6A9

P407

Q37168393-8F3F747F-9A32-4FCB-8CA3-99C61EF775F7

P433

Q37168393-E61FE90B-1316-4DB9-B984-8A904DCBD09B

P478

Q37168393-838FD0E1-9D23-435F-B134-0E2106008D6A

P577

Q37168393-67F2858D-41BF-4973-97AD-1D7DBB0C2ED3

P698

Q37168393-327C374F-9721-4F2B-975D-58C8187BB4A1

P921

Q37168393-85b51a12-9119-4a83-9c0d-22d63095e0f5

Q37168393-E8DE2D1C-676B-43B4-880C-B25A1EE0C048

P932

Q37168393-F3FB89B3-82A8-4F0B-B228-5496137C7F81

P356

JBC.M113.480483

P1433

Journal of Biological Chemistry

P1476

Development of a human IgG4 bi ...... erleukin-13 (IL-13) cytokines.

@en

P2093

Christoph Spiess

http://www.w3.org/2001/XMLSchema#string

Dorothea Reilly

http://www.w3.org/2001/XMLSchema#string

Enzo Palma

http://www.w3.org/2001/XMLSchema#string

Eric Stefanich

http://www.w3.org/2001/XMLSchema#string

Gerald Nakamura

http://www.w3.org/2001/XMLSchema#string

Germaine Fuh

http://www.w3.org/2001/XMLSchema#string

Glen Giese

http://www.w3.org/2001/XMLSchema#string

Heleen Scheerens

http://www.w3.org/2001/XMLSchema#string

Hongbin Liu

http://www.w3.org/2001/XMLSchema#string

J Michael Elliott

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system

Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists.

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair

Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab

IL-13 effector functions

The IL-4 receptor: signaling mechanisms and biologic functions

Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target

An efficient route to human bispecific IgG.

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.

P304

26583-26593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M113.480483

http://www.w3.org/2001/XMLSchema#string

P407

P433

37

http://www.w3.org/2001/XMLSchema#string

P478

288

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23880771

http://www.w3.org/2001/XMLSchema#string

P921

P932

3772205

http://www.w3.org/2001/XMLSchema#string